Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study
Coadministration of GPS and nivolumab reported a tolerable toxicity profile and induced immune responses in a subset of patients, but initial response and survival benefit were limited possibly owing to the small sample size.
Authors
- Philip Wong (ORCID: https://orcid.org/0000-0002-5945-6219)
- Michael David Offin (ORCID: https://orcid.org/0000-0002-7959-3018)
- Michelle S. Ginsberg (ORCID: https://orcid.org/0000-0003-0304-110X)
- Marjorie G. Zauderer (ORCID: https://orcid.org/0000-0002-6109-5790)
- Prashasti Agrawal
- Prasad S. Adusumilli (ORCID: https://orcid.org/0000-0002-1699-2046)
- Victoria Lai (ORCID: https://orcid.org/0000-0002-3641-2248)
- Valerie W. Rusch (ORCID: https://orcid.org/0000-0003-2345-6900)
- Jennifer L. Sauter (ORCID: https://orcid.org/0000-0001-6987-2294)
- Teresa Ho
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100756
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Conquer Cancer Foundation
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center
- National Cancer Institute